Regeneron Reports Strong Q3 2026 Results Driven by Sanofi Collaboration and Libtayo Growth
Regeneron (REGN) reported robust third-quarter 2026 financial results, with total revenue reaching $5.1 billion, a 36% increase year-over-year. This growth was primarily fueled by a significant surge in Sanofi collaboration revenue, which rose 68% to $2.7 billion as the company began recording its full share of profits. Additionally, Libtayo saw substantial momentum with global sales increasing 51%, reaching an annual run rate of approximately $2.2 billion. Despite these successes, the company faces headwinds in its retinal franchise. U.S. EYLEA sales declined by 41% as patients transitioned to the high-dose EYLEA HD formulation and faced increased competition from 2-milligram biosimilars. However, EYLEA HD showed strong performance with $699 million in U.S. sales, growing 62%. The company maintains a strong liquidity position with $16.2 billion in cash and marketable securities to support its extensive R&D pipeline and capital allocation strategies.
Topics: Drug Sales Dupixent EPS EYLEA HD Libtayo Revenue Growth Sanofi Collaboration